-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new coronavirus variant SARS-CoV-2 B.
1.
617 was confirmed in India in October 2020
.
Since then, it has become dominant in some areas of India and the United Kingdom, and has further spread to many countries
immunity
B.
1.
617.
2, also known as variant Delta, is believed to spread faster than other variants
.
The Delta variant has been detected in many countries
At present, little is known about the sensitivity of the variant Delta to the humoral immune response
.
Recent reports indicate that members of the B.
Recently, researchers isolated an infectious Delta strain from a traveler returning from India and studied its sensitivity to monoclonal antibodies (mAbs) and antibodies in the sera of COVID-19 survivors or vaccine recipients Sex, and compared with other virus strains
.
The results show that the variant Delta is resistant to neutralization of some anti-NTD and anti-RBD mAbs (including Bamlanivimab), and the binding of these mAbs to Spike is affected
.
The efficacy of the convalescent patient's serum collected within 12 months after the onset of symptoms on the variant Delta is 4 times lower than that of the variant Alpha (B.
Some anti-Delta variants and anti-NTD of RBD mAbs (including Bamlanivimab) neutralization resistant variants of anti-Delta some of NTD and mAbs anti-RBD (including Bamlanivimab) and resistant in sera of patients recovering the variant The efficacy of Delta is 4 times lower than that of variant Alpha .
New coronavirus variants are neutralized by therapeutic antibodies
The case where the new coronavirus variant is neutralized by the therapeutic antibody The case where the new coronavirus variant is neutralized by the therapeutic antibodyIn addition, the sera of people who have received a dose of Pfizer or AstraZeneca vaccine have almost no inhibitory effect on the variant Delta
.
After using two doses of the vaccine, 95% of people had a neutralization reaction, but the titre to Delta was 3 to 5 times lower than that of Alpha
The serum of a person who has received a dose of Pfizer or AstraZeneca vaccine has almost no inhibitory effect on the variant Delta.
Original source:
Original source:Delphine Planas et al.
Delphine Planas et al.
Leave a message here
